Academic Journal
A call for clinical trial globalization in Alzheimer's disease and related dementia
| العنوان: | A call for clinical trial globalization in Alzheimer's disease and related dementia |
|---|---|
| المؤلفون: | Llibre-Guerra, J. J., Heavener, A., Brucki, S. M. D., Marante, J. P. D., Pintado-Caipa, M., Chen, Yaohua, Behrens, M. I., Hardi, A., Admirall-Sanchez, A., Akinyemi, R., Alladi, S., Dorsman, K. A., Rodriguez-Salgado, A. M., Solorzano, J., Babulal, G. M. |
| المساهمون: | Washington University School of Medicine Saint Louis, MO, Harvard Medical School Boston (HMS), Universidade de São Paulo = University of São Paulo (USP), Lille Neurosciences & Cognition - U 1172 (LilNCog), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Hospital Clínico Universidad de Chile, Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), Trinity College Dublin, University of Ibadan, National Institute of Mental Health and Neurosciences Bagalore, India, University of Texas Southwestern Medical Center Dallas, University of Johannesburg South Africa (UJ) |
| المصدر: | ISSN: 1552-5260 ; EISSN: 1552-5279. |
| بيانات النشر: | CCSD Alzheimer's Association / Wiley |
| سنة النشر: | 2024 |
| المجموعة: | LillOA (HAL Lille Open Archive, Université de Lille) |
| مصطلحات موضوعية: | [SDV]Life Sciences [q-bio] |
| الوصف: | International audience ; Background: The burden of Alzheimer's disease and related dementia (ADRD) is projected to disproportionally impact low-middle-income countries (LMICs). However, there is a systematic under-representation of LMICs in ADRD clinical trial platforms.Methods: We aimed to determine the global distribution of ADRD clinical trials and identify existing barriers for conducting clinical trials in LMICs. Primary data sources to identify trial distribution in LMICs included ClinicalTrials.gov and the International Trials Registry Platform. An additional systematic review and expert consensus interviews were conducted to identify barriers for conducting clinical trials in LMICs.Findings: Among 1237 disease-modifying therapies tested in ADRD clinical trials, only 11.6% have been or are conducted in emerging economies (upper-middle income [9.6%] and low-middle income [2.0%]). We identified several limitations for trial implementation including a lack of financial resources, low industry presence, regulatory obstacles, and operational barriers INTERPRETATION: Although LMICs bear the greatest burden of ADRD globally, substantial development of clinical trial platforms to address this inequity and health disparity is lacking. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/36840622; PUBMED: 36840622 |
| DOI: | 10.1002/alz.12995 |
| الاتاحة: | https://hal.univ-lille.fr/hal-04845744 https://doi.org/10.1002/alz.12995 |
| رقم الانضمام: | edsbas.6FFEFF3A |
| قاعدة البيانات: | BASE |
| DOI: | 10.1002/alz.12995 |
|---|